CRBP
Corbus Pharmaceuticals Holdings, Inc.
OpenVolumeMkt capP/EEPSDiv yield
Day – 52-wk –
Expected move
InputsNext report
Last report
Largest filed tie
13F top-10 QoQ
Top fund weight
Corbus Pharmaceuticals has 5 disclosed suppliers and 0 disclosed customers in SEC filings.
Last reportshaded = implied▲▼ = realized× = |realized| ÷ implied
SentenceWe are dependent on our licensing partner, CSPC, to manufacture antibody drug conjugates and we do not have control over their chemistry, manufacturing, and control strategy for CRB-701 to ensure successful development and supply of drug to commence clinical studies or support commercial demand.
CRBP 10-Kaccession 0001193125-26-098530
SentencePursuant to the terms of the license agreement (the "Jenrin License Agreement") with Jenrin Discovery, LLC ("Jenrin"), we are obligated to pay potential milestone payments to Jenrin totaling up to $18.4 million for each compound we elect to develop based upon the achievement of specified development and regulatory milestones.
CRBP 10-Kaccession 0001193125-26-098530
SentenceInterest expense relates primarily to interest expense on a loan from K2 HealthVentures LLC.
CRBP 10-Kaccession 0001193125-26-098530
SentencePursuant to the terms of the license agreement (the "UCSF License Agreement") with the Regents of the University of California, we are obligated to pay up to $150.8 million in remaining potential milestone payments based upon the achievement of specified development and regulatory milestones, excluding indication milestones for antibodies used for diagnostic products and services that will be an additional $50.0 thousand for each new indication.
CRBP 10-Kaccession 0001193125-26-098530
SentenceWe are a party to license agreements with Jenrin and The Regents pursuant to which we licensed exclusive worldwide rights to develop, manufacture and market drug candidates.
CRBP 10-Kaccession 0001193125-26-098530
Corbus Pharmaceuticals Holdings, Inc.
4.20
Largest filed tie
—
—
—
Expected move
No implied move.